CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Fresenius signs exclusive development deal with WuXi Biologics to expand biosimilars pipeline

By Public Technologies
  • Fresenius entered an exclusive development agreement with WuXi Biologics, securing options for up to 37 biosimilar candidates over the next decade.
  • The deal could expand its marketed and pipeline portfolio from 29 to 66 molecules, targeting over €370 billion in originator sales.
  • Selected programs will use fee-for-service payments, with Fresenius retaining exclusive global commercialization rights and full product economics.
  • Manufacturing strategy remains under its control, including potential transfers of selected products to wholly owned mAbxience.
  • Operating cash flow will fund the agreement without new financing; 2026 guidance and the existing 2030 Biopharma ambition remain unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_en) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk